finance.yahoo.comNOV 32 min read$SIBN

SiBone Q3 Earnings Call Highlights

SiBone (SIBN) reported Q3 earnings, highlighting strong demand for its Onyx platform, which targets a $1.5B market. Gross profit rose 13.7% to $44.2M, with gross margin at 79.3%. Net loss narrowed to $3.6M. The company reaffirmed 2026 revenue guidance of $231M-$233M and expects Q4 momentum from physician growth and new products.

Original reporting

finance.yahoo.com

Published Nov 3, 2026, 1:14 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 3, 2026, 1:31 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

SiBone Q3 Earnings Call Highlights — source image — Source · finance.yahoo.com

Decision brief

The 30-second read

$SIBNBullishMed

Why it matters

Earnings beat on margin and cash flow, with guidance unchanged, suggest near‑term stability but future upside depends on Onyx adoption and reimbursement.

Market read

The earnings release provides fresh data for traders; the product launch may drive future growth.

What to watch

Pending CMS reimbursement decisions for Onyx could materially affect future revenue.

Relevance 7/10Novelty 7/10Timing: after market release

Background

SiBone (NASDAQ:SIBN) reported Q3 results, highlighted launch of new spinal fusion product Onyx, and reaffirmed 2026 guidance.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$SIBNBullishHigh confidence

Context

Q3 earnings disclosed revenue, margin, cash flow and reaffirmed 2026 guidance, plus launch details for Onyx.

Expected impact

likely modest upside as market prices in stronger margins and cash position

Evidence & confidence

Improved gross margin to 79.3% and narrowed net loss signal operational leverage; guidance unchanged reduces uncertainty.

Market effects

Sector

Positive for spinal fusion device sector as new product Onyx gains early traction.

Regional

U.S. medical device market may see modest uplift from SiBone's earnings beat.

Global

Limited to investors focused on niche orthopedic devices.

Counterpoint

What could challenge this read

Margin pressure could rise once Onyx scales, potentially offsetting short‑term gains.

Key entities

Company
SiBone Inc.
Medical device maker focusing on sacroiliac joint fusion.
Product
Onyx
New spinal fusion platform launched by SiBone.

Read at source ← All news

NOV 3

$SIBNMed

SI-Bone Q3 Loss Narrows As Revenue Rises 14.5%; Reaffirms FY26 Revenue Outlook

SI-BONE (SIBN) reported a narrower Q3 loss of $3.62M, with revenue up 14.5% to $55.7M. The company reaffirmed FY26 revenue guidance of $231M-$233M and adjusted EBITDA expectations. U.S. revenue grew 13.9%, driven by procedure volume, while international revenue rose 27%. Cash and investments totaled $146.26M. The stock closed at $20.22, down 4.76%.

rttnews.com2 min

NOV 3

$SIBNMed

SI-BONE (SIBN) Q3 2026 Earnings Call Transcript

SI-BONE (SIBN) reported Q3 2026 earnings, highlighting 27% international revenue growth and 32% adjusted EBITDA increase. The company launched iFuse Granite Onyx, expanding its market to 650,000 procedures and $5B opportunity. Onyx targets spinal fusion failure points, with early demand exceeding expectations. New DRGs and reimbursement enhancements support growth. The company expects 20%+ revenue growth in Q4 2026.

finance.yahoo.com3 min

NOV 2

$SIBNHigh

SI-BONE, Inc. Reports Financial Results for the Third Quarter 2026 and Reaffirms 2026 Revenue Guidance

SI-BONE, Inc. (SIBN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SI-BONE, Inc. Reports Financial Results for the Third Quarter 2026 and Reaffirms 2026 Revenue Guidance Delivered ~20% U.S. procedure volume growth in the third quarter Third Quarter 2026 Financial Highlights (all comparisons are to the prior year period) • Worldwide

SEC EDGAR 8-K2 min

OCT 2

$EWHighAI 8/10

Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

rttnews.com3 min

SEP 29

$SIBNMedAI 8/10

BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™ Extending Its Compromised Bone Franchise Beyond the Pelvis – Ortho Spine News

SI-BONE (SIBN) received FDA 510(k) clearance for the iFuse Granite Onyx System, expanding its compromised bone solutions beyond the pelvis. The device targets spinal fusion issues in low-density bone, addressing a 27% loosening risk. The company aims to broaden its market and improve patient outcomes.

orthospinenews.com2 min

SEP 28

$SIBNHighAI 8/10

SI-Bone stock gains after FDA clears spinal fusion system

SI-Bone Inc (SIBN) shares rose 2.8% after receiving FDA 510(k) clearance for its iFuse Granite Onyx System, its first product for spinal fusion outside the pelvis. The system aims to address screw loosening in spinal fusions. CEO Laura Francis noted it is the company's third breakthrough device designation.

investing.com2 min